<DOC>
	<DOCNO>NCT01662869</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled study evaluate efficacy safety onartuzumab ( MetMAb ) combination 5-fluorouracil , folinic Acid , oxaliplatin ( mFOLFOX6 ) participants metastatic human epidermal growth receptor ( HER ) 2-negative MET-positive adenocarcinoma stomach gastroesophageal junction . Participants randomize 1:1 ratio receive either onartuzumab placebo combination mFOLFOX6 . Participants may continue receive onartuzumab placebo disease progression , unacceptable toxicity , participant physician decision discontinue treatment .</brief_summary>
	<brief_title>A Study Onartuzumab Combination With mFOLFOX6 Participants With Metastatic HER2-Negative MET-Positive Gastroesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Adenocarcinoma stomach gastroesophageal junction inoperable , metastatic disease , amenable curative therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great ( &gt; ) 3 month Presence tissue sample IHC assay MET receptor HER2 status Tumor ( primary metastatic lesion ) define METpositive IHC Measurable disease nonmeasurable evaluable disease , accord RECIST v1.1 ; Participants peritoneal disease would generally regard evaluable disease allow enter trial For woman postmenopausal surgically sterile ; agreement use adequate method contraception ( hormonal implant ) treatment period least 90 day last dose onartuzumab/placebo 6 month last dose oxaliplatin For men : agreement use barrier method contraception treatment period 90 day last dose onartuzumab/placebo 6 month last dose oxaliplatin HER2positive tumor ( primary tumor metastasis ) Previous chemotherapy locally advance metastatic gastric carcinoma ( adjuvant neoadjuvant chemotherapy must complete least 6 month prior randomization ) Prior treatment investigational drug target human growth factor ( HGF ) MET pathway History another malignancy within previous 5 year , except appropriately treat presume cured carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , localize prostate cancer Pregnancy lactation Receipt investigational drug within 28 day prior study start Clinically significant gastrointestinal abnormality , apart gastric cancer , include uncontrolled inflammatory gastrointestinal disease Significant history cardiac disease Significant vascular disease Serious active infection time randomization , serious underlie medical condition would impair ability participant receive protocol treatment Infection human immunodeficiency virus , hepatitis B , hepatitis C Radiotherapy within 4 week start study treatment Major surgery within 4 week start study treatment , without complete recovery Any condition ( psychological , geographical ) permit compliance study followup procedures Peripheral neuropathy Prior unanticipated severe reaction fluoropyrimidine therapy Known sensitivity contraindication component study treatment Active gastrointestinal bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>